DNA X, Inc.
- SONM ยท Nasdaq
- Telephone & Telegraph Apparatus
- San Diego, CA
- 4 employees
- CIK 0001178697
Updated from SEC filings through
Top things to know
Executives
- Mike Mulica Chief Executive Officer 8-K, 2026-08-27
- Michael C. Mulica Acting CEO 4, 2026-02-10
- Clay Crolius Chief Financial Officer 10-K, 2026-04-15
- Clayton Crolius Chief Financial Officer 4, 2026-02-10
- Peter Liu our current Chief Executive Officer DEF 14A, 2025-09-19
What leadership is saying
“Having successfully completed a strategic exit from our legacy business, management has made a deterministic decision to reallocate our resources into the high-growth, high-margin decentralized AI and crypto trading sectors”
Earnings press release (8-K Ex. 99.1), filed May 20, 2026
DNA X, Inc. is a U.S. public company in telephone & telegraph apparatus (SIC 3661), headquartered in San Diego, CA. It trades as SONM on Nasdaq. Revenue was $58.3M in the fiscal year ending December 31, 2024, -37.7% from the year before. It reported about 4 employees. Mike Mulica is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | Not on file | $58.3M 10-K, 2025-03-31 | $93.6M 10-K, 2025-03-31 | $69.8M 10-K, 2024-03-27 | $54.6M 10-K, 2023-03-20 |
| Operating income | -$5.4M 10-K, 2026-04-15 | -$3.1M 10-K, 2026-04-15 | $513K 10-K, 2025-03-31 | -$14.3M 10-K, 2024-03-27 | -$38.0M 10-K, 2023-03-20 |
| SG&A | $5.4M 10-K, 2026-04-15 | $16.1M 10-K, 2026-04-15 | $17.0M 10-K, 2025-03-31 | $17.9M 10-K, 2024-03-27 | $19.9M 10-K, 2023-03-20 |
| Net income | -$20.7M 10-K, 2026-04-15 | -$33.6M 10-K, 2026-04-15 | -$90K 10-K, 2025-03-31 | -$14.1M 10-K, 2024-03-27 | -$38.6M 10-K, 2023-03-20 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Mike Mulica | Chief Executive Officer | 8-K, 2026-08-27 |
| Michael C. Mulica | Acting CEO | 4, 2026-02-10 |
| Peter Hao Liu | Board member (per proxy) bio: Chief Executive Officer | DEF 14A, 2025-09-19 |
| Peter Liu | Named in proxy bio: our current Chief Executive Officer | DEF 14A, 2025-09-19 |
| Clay Crolius | Chief Financial Officer | 10-K, 2026-04-15 |
| Clayton Crolius | Chief Financial Officer | 4, 2026-02-10 |
| Charles Becher | Board member (per proxy) bio: Chief Commercial Officer and General Manager of North America | DEF 14A, 2025-09-19 |
| George Thangadurai | Director | 10-K, 2026-04-15 |
| Jack Steenstra | Director | 10-K, 2026-04-15 |
| James Cassano | Director | 10-K, 2026-04-15 |
| Scott Walker | Director | 10-K, 2026-04-15 |
What DNA X, Inc. does
Add new products that will bring new users to our platform and provide us with additional opportunities to generate fees from new and existing users. Possible products are staking (borrowing assets to allow user to receive fees that are analogous to interest) and loaning funds from held customer assets.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 1.5 million (as of August 18, 2026) | 10-Q, August 19, 2026 |
|---|---|---|
| Public float | $12.6M (as of June 30, 2025) | 10-K/A, April 30, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 19, 2026 |
| Latest proxy statement | Meeting September 19, 2025 (filed September 19, 2025) | DEF 14A, September 19, 2025 |
| Auditor | Baker Tilly US, LLP (San Jose, CA) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-08-31
- Item 8.01 Other events
- 8-K filed 2026-08-27
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-07-02
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- Item 3.03 Material modification to rights of security holders
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- 8-K filed 2026-06-04
- Item 1.02 Termination of a material definitive agreement
- 8-K filed 2026-05-27
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 3.01 Notice of delisting or failure to meet listing standards
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2026-05-20
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-30
- Item 4.01 Changes in registrant's certifying accountant
- 8-K filed 2026-04-15
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-10
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-02-05
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about DNA X, Inc.
- What does DNA X, Inc. do?
- In its own words, from Item 1 of its 10-K: "Add new products that will bring new users to our platform and provide us with additional opportunities to generate fees from new and existing users. Possible products are staking (borrowing assets to allow user to receive fees that are analogous to interest) and loaning funds from held customer assets."
- What is DNA X, Inc.'s revenue?
- $58.3M for the fiscal year ending December 31, 2024, from its 10-K filed March 31, 2025.
- Is DNA X, Inc. profitable?
- DNA X, Inc. reported net income of -$33.6M for the fiscal year ending December 31, 2024.
- How many employees does DNA X, Inc. have?
- About 4 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of DNA X, Inc.?
- Mike Mulica, Chief Executive Officer, as named in a 8-K filed August 27, 2026.
- Who is the CFO of DNA X, Inc.?
- Clay Crolius, Chief Financial Officer, as named in a 10-K filed April 15, 2026.
- Where is DNA X, Inc. headquartered?
- San Diego, CA.
- What is DNA X, Inc.'s stock ticker?
- SONM on Nasdaq.
- What industry is DNA X, Inc. in?
- Telephone & Telegraph Apparatus, SIC code 3661.
- What is DNA X, Inc.'s website?
- dna-x.global.
- When does DNA X, Inc. report earnings next?
- November 6, 2026. Source: ir_event.
- Is DNA X, Inc. a public company?
- Yes. DNA X, Inc. files with the SEC under CIK 0001178697 and trades as SONM.
- Who audits DNA X, Inc.?
- Baker Tilly US, LLP, San Jose, CA, as named in its latest annual report (10-K).
- How many shares of DNA X, Inc. are outstanding?
- 1.5 million shares as of August 18, 2026, from its 10-Q filed August 19, 2026.
- What is DNA X, Inc.'s public float?
- $12.6M as of June 30, 2025, as reported on the cover of its 10-K/A filed April 30, 2026.
- How many business segments does DNA X, Inc. report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 19, 2026.
- When is DNA X, Inc.'s annual shareholder meeting?
- September 19, 2025, per its proxy statement (DEF 14A) filed September 19, 2025.